271 related articles for article (PubMed ID: 30543029)
1. Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence.
Gupta KK; Ali S; Sanghera RS
Cardiol Ther; 2019 Jun; 8(1):5-20. PubMed ID: 30543029
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS
Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198
[TBL] [Abstract][Full Text] [Related]
4. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
5. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
Kones R; Rumana U
Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
[TBL] [Abstract][Full Text] [Related]
6. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
[TBL] [Abstract][Full Text] [Related]
7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis.
Strålberg T; Nordenskjöld A; Cao Y; Kublickiene K; Nilsson E
Eur J Clin Invest; 2019 Jul; 49(7):e13113. PubMed ID: 30921469
[TBL] [Abstract][Full Text] [Related]
9. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
10. Keep recycling going: New approaches to reduce LDL-C.
Klein-Szanto AJP; Bassi DE
Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke.
Ntaios G; Milionis H
Int J Stroke; 2019 Jul; 14(5):476-482. PubMed ID: 31092149
[TBL] [Abstract][Full Text] [Related]
12. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
[TBL] [Abstract][Full Text] [Related]
13. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
[TBL] [Abstract][Full Text] [Related]
15. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
[TBL] [Abstract][Full Text] [Related]
16. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
[TBL] [Abstract][Full Text] [Related]
17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
19. A short review of proprotein convertase subtilisin/kexin type 9 inhibitors.
Alali RA
Rev Cardiovasc Med; 2019 Mar; 20(1):1-8. PubMed ID: 31184090
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
